Palatin Technologies (PTN) investor relations material

Executive summary

• Strategic focus on developing next-generation MC4R agonists for rare and syndromic obesity disorders, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome.

• Advancing non-lipidated peptide, lipidated peptide (PL1000, PL2000), and oral small molecule MC4R agonists, aiming for improved efficacy, tolerability, and minimal hyperpigmentation.

• Significant progress in preclinical studies, with lead candidates showing potent MC4R activity and promising pharmacokinetics for less frequent dosing.

• Strategic collaborations, including a major agreement with Boehringer Ingelheim and a sub-license with Altanispac Labs, provide non-dilutive funding and research opportunities.

• Multiple partnering and out-licensing activities in retinal diseases, dry eye disease, ulcerative colitis, and diabetic nephropathy.

Financial highlights

• Fiscal 2026 collaboration and license revenue totaled $13.2 million, including $9.4 million from Boehringer Ingelheim and $3.8 million from Altanispac (non-cash debt cancellation), compared to no revenue in fiscal 2025.

• Q4 operating expenses were $4.7 million, up from $2.3 million year-over-year; full-year operating expenses rose to $21.9 million from $17.5 million.

• Net loss for fiscal 2026 was $8.4 million, a significant improvement from $17.3 million in fiscal 2025.

• Net cash used in operations was $13.5 million, down from $21.3 million in 2025; cash and equivalents at year-end were $7.5 million.

• Net cash provided by financing activities was $18.5 million, mainly from equity and warrant sales.

Outlook and guidance

• IND filing and phase I studies for the lipidated peptide candidate targeted for the first half of 2027, with data expected in the second half.

• Oral MC4R program phase I studies planned for the second half of 2027, with initial data in the first half of 2028.

• Anticipates milestone revenue from Boehringer Ingelheim within the next two to three quarters; Altanispac milestones are further out.

• Operating expenses expected to increase in the first half of 2027 as development activities ramp up.

• Additional funding required to advance development programs and fund operations; substantial doubt exists about ability to continue as a going concern.